BioSpace News Archive

NLS Pharmaceutics Ltd. announced today that it received notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market, as discussed more fully below.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company’s virtual Annual General and Special Meeting of Shareholders (the “AGM”) will be webcast on June 26, 2024, at 4:30 p.m. EDT.

FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) announced the development of a novel artificial thymus organoid that can restore immune function in a severe combined immunodeficiency (SCID) mouse model.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced its plans for the development of a new drug candidate, NVG-300

Medline, a market-leading manufacturer and supplier of medical supplies and solutions, announced that it achieved the Diamond-level HIRC Resiliency Badge for distribution, a recognition of the company’s relentless commitment to resiliency within the healthcare supply chain.

The Pediatric Brain Tumor Foundation announced the appointment of Ursula Burns and Jordan Wertlieb as inaugural members of the organization’s new Advisory Board.

Strenge Spine Center, a pioneering provider of advanced spine care, is proud to announce the launch of its state-of-the-art technologies and innovative treatment options, including the EOSedge system.

Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 study1 comparing weekly and monthly subcutaneous (SC) buprenorphine injections (Buvidal®/Brixadi®) to daily sublingual buprenorphine/naloxone (SL-BPN/NX).

Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2024 (“FYE 2024”), and provided an update on the Company’s strategy for fiscal 2025.